by Alex Brown | Apr 19, 2023 | Blog
In the past, the FDA only accepted clinical studies that were conducted in the United States. However, in recent years, the FDA has begun to accept clinical studies that were conducted in other countries. This is because the FDA recognizes that high-quality clinical...
by Alex Brown | Feb 27, 2023 | Blog
Pharmaceutical innovation stems from a variety of sources. Practicing doctors and healthcare providers generate concepts and collect observational data for new and improved treatments using existing approved medication. Alternatively, university researchers study...
by Alex Brown | Feb 8, 2023 | Blog
Vici Health Sciences, a customer-focused pharmaceutical CDMO that offers formulation development services, R&D program management, FDA regulatory support, phase 1 and phase 2 cGMP clinical batch manufacturing has added DEA scheduled 1-5 controlled substances...
by Alex Brown | Feb 1, 2023 | Blog
Nitrosamine compounds have long been considered probable human carcinogens. Nitrosamines are produced by the reaction of nitrites and secondary amines. Nitrosamine compounds are ubiquitous in food, beverages, and the environment. In 2018, angiotensin II receptor...
by Alex Brown | Jan 17, 2023 | Blog
Why must companies consider formulation patents? Pharmaceutical drug development is a costly endeavor. It is critical that pharmaceutical companies secure return on investment in their innovation. Valuation of smaller, pre-revenue companies often depends on the...
by Alex Brown | Jan 10, 2023 | Blog
Choosing the right organization to develop drugs is the single most important decision a small or mid-size pharmaceutical company is faced with after selecting the molecule and indication. There are many different types of organizations to choose from. Some...
